Takeda Pharmaceutical Company Ltd

🇸🇪Sweden

Country: 🇸🇪Sweden

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

Vonoprazan Study in Patients With Erosive Esophagitis to Evaluate Long-term Safety

Phase 4

Completed

Conditions: Erosive Esophagitis

Interventions: Drug: Vonoprazan
Drug: Lansoprazole

First Posted Date: 2016-02-10

Last Posted Date: 2023-12-13

Lead Sponsor: Takeda

Target Recruit Count: 208

Registration Number: NCT02679508

Locations: 🇯🇵
Tokatsu Tsujinaka Hospital, Abiko, Chiba, Japan
🇯🇵
Hakodate Hospital, Hakodate, Hokkaido, Japan
🇯🇵
Shiga University Of Medical Science Hospital, Otsu, Shiga, Japan

and more 33 locations

OTIS Vedolizumab Pregnancy Exposure Registry

Completed

Conditions: Colitis, Ulcerative
Crohn's Disease

Interventions: Drug: Vedolizumab
Biological: Other Biological Agent

First Posted Date: 2016-02-09

Last Posted Date: 2024-10-07

Lead Sponsor: Takeda

Target Recruit Count: 303

Registration Number: NCT02678052

Entyvio (Vedolizumab) Long Term Safety Study

Completed

Conditions: Ulcerative Colitis and Crohn's Disease

Interventions: Other: Other Biologic Agents
Drug: Vedolizumab

First Posted Date: 2016-02-04

Last Posted Date: 2024-10-31

Lead Sponsor: Takeda

Target Recruit Count: 5302

Registration Number: NCT02674308

Locations: 🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸
University of South Alabama, Mobile, Alabama, United States
🇺🇸
University of Arizona Medical Center, Tucson, Arizona, United States

and more 281 locations

The Exploratory Study to Investigate the Effect of Ramelteon for Insomnia Patients With Major Depressive Disorder by Using Actigraphy

Phase 4

Completed

Conditions: Major Depressive Disorder
Insomnia

Interventions: Drug: Ramelteon

First Posted Date: 2016-01-29

Last Posted Date: 2019-07-22

Lead Sponsor: Takeda

Target Recruit Count: 26

Registration Number: NCT02669082

Locations: 🇯🇵
Sangenjaya Neurology and Psychosomatic Clinic, Setagaya, Tokyo, Japan
🇯🇵
Himorogi Kokorono Clinic, Shinjuku, Tokyo, Japan
🇯🇵
Ishikawa Mental Clinic, Sapporo, Hokkaido, Japan

and more 4 locations

Efficacy and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-like Particle Vaccine in Adults

Phase 2

Completed

Conditions: Healthy Volunteers

Interventions: Biological: NoV GI.1/GII.4 Bivalent VLP Vaccine
Biological: NoV Placebo-matching Saline

First Posted Date: 2016-01-29

Last Posted Date: 2021-06-10

Lead Sponsor: Takeda

Target Recruit Count: 4748

Registration Number: NCT02669121

Locations: 🇺🇸
Great Lakes Naval Station, Great Lakes, Illinois, United States

Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine in an Elderly Population

Phase 2

Completed

Conditions: Norovirus

Interventions: Biological: Norovirus GI.1/GII.4 Bivalent VLP Vaccine
Drug: 0.9% sodium chloride (saline)

First Posted Date: 2016-01-22

Last Posted Date: 2020-05-18

Lead Sponsor: Takeda

Target Recruit Count: 320

Registration Number: NCT02661490

Locations: 🇺🇸
Johnson County Clin-Trials, Lenexa, Kansas, United States
🇺🇸
University of Rochester, Rochester, New York, United States
🇺🇸
Simon Williamson Clinic, Birmingham, Alabama, United States

and more 7 locations

A Phase 3 Study to Evaluate the Efficacy and Safety of Relugolix (TAK-385) 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids

Phase 3

Completed

Conditions: Uterine Fibroids

Interventions: Drug: Relugolix
Drug: Relugolix Placebo
Drug: Leuprorelin
Drug: Leuprorelin Placebo

First Posted Date: 2016-01-13

Last Posted Date: 2019-03-22

Lead Sponsor: Takeda

Target Recruit Count: 281

Registration Number: NCT02655237

A Placebo-Controlled, Phase 3 Study of Relugolix (TAK-385) 40 mg in the Treatment of Pain Symptoms Associated With Uterine Fibroids

Phase 3

Completed

Conditions: Uterine Fibroids

Interventions: Drug: Relugolix placebo
Drug: Relugolix

First Posted Date: 2016-01-13

Last Posted Date: 2019-03-22

Lead Sponsor: Takeda

Target Recruit Count: 65

Registration Number: NCT02655224

Lubiprostone for the Treatment of Chronic Idiopathic Constipation

Phase 3

Completed

Conditions: Constipation

Interventions: Drug: Placebo
Drug: Lubiprostone

First Posted Date: 2016-01-08

Last Posted Date: 2018-08-13

Lead Sponsor: Takeda

Target Recruit Count: 204

Registration Number: NCT02651155

Vedolizumab IV 300 mg in the Treatment of Fistulizing Crohn's Disease

Phase 4

Completed

Conditions: Crohn's Disease

Interventions: Drug: Vedolizumab
Drug: Placebo

First Posted Date: 2015-12-15

Last Posted Date: 2019-11-19

Lead Sponsor: Takeda

Target Recruit Count: 34

Registration Number: NCT02630966

Locations: 🇫🇷
Hopital de Brabois, Vandoeuvre les Nancy, France
🇫🇷
Hopital l'Archet II, Nice Cedex 3, France
🇳🇱
Academic Medical Center, Amsterdam, Netherlands

and more 15 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy